NCT03420508 2026-02-05
Treating Patients With Melanoma and ALK Alterations With Ensartinib
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07235306 2025-11-19
Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06779539 2025-01-17
Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer
West China Hospital
Phase 2 Not yet recruiting
NCT06780839 2025-01-17
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06762327 2025-01-07
Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
Nanjing First Hospital, Nanjing Medical University
Phase 2 Not yet recruiting
NCT06563999 2024-12-10
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT05491811 2024-09-19
EAGLE
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05241028 2023-10-10
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT03574402 2022-12-06
TRUMP
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT05186506 2022-01-11
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
Sichuan University
Phase 2 Not yet recruiting
NCT05178511 2022-01-05
ERSGATR
Sun Yat-sen University
Phase 2 Unknown